Pharmstandard

Pharmstandard

Russian pharmaceutical company committed to the development and manufacture of advanced, high-quality, affordable medicines.

Pharmstandard is a Russian pharmaceutical company developing and manufacturing medicines of various pharmacotherapeutic groups, including those for treatments of cardiovascular diseases, diabetes mellitus, growth hormone deficiency, gastroenterological and infectious diseases, neurological disorders, metabolic disorders, oncology, and a variety of other diseases.

The company’s total manufacturing capacity exceeds 1.7 billion packs per year. Pharmstandard manufacturing facilities comprise 5 state-of-the-art pharmaceutical factories:

  • Phs-Leksredstva JSC (Kursk),
  • Pharmstandard-UfaVITA JSC (Ufa),
  • PHS-Tomskhimpharm JSC (Tomsk),
  • Lekko CJSC (Volginsky settlement, Vladimir Region),
  • J.S.C. Biomed- Mechnikov (Moscow, Moscow Region),

Pharmstandard LLC (Moscow) manages raw material purchase and supply to ensure the subsequent manufacturing of pharmaceutical products at Pharmstandard facilities.

Covid-19 Treatment

Pharmstandard is assessing Arbidol (Umifenovir), a membrane fusion inhibitor developed as a treatment for influenza, for the treatment of Covid-19. Clinical trials are ongoing for Arbidol as a monotherapy and in combinations that include AbbVie’s Kaletra, Ascletis Pharma’s ASC09, lopinavir, ritonavir, carrimycin, and Bromhexine Hydrochloride. China’s Ruijin Hospital is conducting the monotherapy trial, while various Chinese hospitals are investigating the combination therapies.

Timeline

People

Name
Role
LinkedIn

Sergey Dushelikhinsky

Commercial Officer

Grigory Potapov

Chief Executive Officer

Viktor Fedlyuk

Deputy CEO for Legal Affairs

Viktor Kharitonin

Executive Director

Vladimir Chupikov

Chief Operating Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.